The Electronic Identification and Trust Services for Electronic Transactions Regulations 2016 No. 696

SCHEDULE 3 U.K. Consequential Amendments

Medicines for Human Use (Clinical Trials) Regulations 2004 U.K.

2.  In regulation 2(1) (interpretation) of the Medicines for Human Use (Clinical Trials) Regulations 2004 M1 —

(a) for the definition “electronic signature”, substitute—

““electronic signature” means data in electronic form which is attached to or logically associated with other data in electronic form and which is used by the signatory to sign; ”; and

(b) after the definition of “serious adverse event”, insert—

““signatory” means a natural person who creates an electronic signature;”.

Marginal Citations

M1 S.I. 2004/1031, to which there are amendments not relevant to these Regulations.